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Abstract
Purpose CRISPR gene-editing technology has the potential to transform the diagnosis and treatment of infectious diseases, 
but most clinicians are unaware of its broad applicability. Derived from an ancient microbial defence system, these so-called 
“molecular scissors” enable precise gene editing with a low error rate. However, CRISPR systems can also be targeted 
against pathogenic DNA or RNA sequences. This potential is being combined with innovative delivery systems to develop 
new therapeutic approaches to infectious diseases.
Methods We searched Pubmed and Google Scholar for CRISPR-based strategies in the diagnosis and treatment of infectious 
diseases. Reference lists were reviewed and synthesized for narrative review.
Results CRISPR-based strategies represent a novel approach to many challenging infectious diseases. CRISPR technolo-
gies can be harnessed to create rapid, low-cost diagnostic systems, as well as to identify drug-resistance genes. Therapeutic 
strategies, such as CRISPR systems that cleave integrated viral genomes or that target resistant bacteria, are in development. 
CRISPR-based therapies for emerging viruses, such as SARS-CoV-2, have also been proposed. Finally, CRISPR systems 
can be used to reprogram human B cells to produce neutralizing antibodies. The risks of CRISPR-based therapies include 
off-target and on-target modifications. Strategies to control these risks are being developed and a phase 1 clinical trials of 
CRISPR-based therapies for cancer and monogenic diseases are already underway.
Conclusions CRISPR systems have broad applicability in the field of infectious diseases and may offer solutions to many of 
the most challenging human infections.
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Introduction
The discovery of CRISPR
“Clustered regularly interspaced palindromic repeats” 
(CRISPR) were first discovered in the archaea species, 
Haloferax mediterranei, by a Spanish microbiologist, Dr. 
Francisco Mojica, They comprised palindromic sequences 
of 30 base pairs (bp) interspersed with spacer sequences of 
36 bp [1]. Initially the discovery did not generate interest 
outside the field of microbiology, however, when similar 
palindromic repeats were identified in multiple bacterial 
species, including Escherichia coli, Mycobacterium tuber-
culosis, and Clostridium difficile [2], it became apparent that 
CRISPR repeats might serve an important conserved func-
tion. Protein-coding genes, known as “CRISPR-associated 
proteins” or Cas proteins, with nucleic acid unwinding and 
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cleavage functions were also discovered in proximity to the 
CRISPR sequences [2], but their role remained a mystery.
The function of CRISPR repeats was finally eluci-
dated in 2003, when Dr. Mojica made a key observation. 
While searching for homologies between CRISPR spac-
ers and other known sequences, Mojica identifed matches 
between  some CRISPR spacer sequences and bacterio-
phages, which are viruses that infect bacteria. Mojica pos-
tulated that CRISPR sequences and their associated Cas pro-
teins might function as a microbial defense system, storing 
“memories” of bacteriophages, which could then be used to 
fight subsequent infections [1, 3].
The mechanism of CRISPR function in bacteria is 
remarkably simple (Fig. 1). When a bacterium is invaded 
by a bacteriophage or plasmid, portions of the invading 
DNA are cleaved by Cas proteins and inserted into the 
CRISPR locus, creating a “memory” of the sequence [4]. 
The bacterium constitutively transcribes the  CRISPR 
locus to produce an RNA message that contains all of the 
CRISPR repeats and their spacers. This transcript is called 
the pre-crispr-ribonucleic acid (pre-crRNA). Cleavage of 
the pre-crRNA by a Cas protein produces the crispr-ribo-
nucleic acids (crRNAs), each of which contains a single 
spacer and a single CRISPR repeat [5].
To eliminate invading pathogens, the crRNA segments 
are released into the cytoplasm where they recognize and 
bind matching DNA or RNA sequences. When a match 
is made, a cleavage complex is assembled containing the 
crRNA and its target sequence, Cas nucleases, and a small 
RNA called the trans-activating CRISPR RNA (tracr-
RNA). This complex cleaves the target at a site adjacent to 
the crRNA target sequence, called the protospacer adjacent 
motif (PAM) (Fig. 1).
Cas proteins from different bacterial species mediate 
nucleic acid cleavage in different ways. Some Cas proteins, 
like Cas9, work individually, while others form cleavage 
complexes containing multiple Cas proteins. Irrespec-
tive of the mechanism of cleavage however, the CRISPR 
system acts like an microbial defense system, targeting 
the DNA or RNA of invading agents for degradation and 
elimination.
Fig. 1  CRISPR/Cas9 function 
in bacteria. a Genetic material 
from a virus, phage, or plasmid 
enters the bacterium. b Short 
segments of genetic informa-
tion from the invading agent 
are inserted into the CRISPR 
region interleaved with spacer 
segments. c crRNA segments 
consisting of CRISPR repeats 
and spacers are constitutively 
expressed in the bacterium. d 
Invading nucleic acid segments 
are recognized by crRNAs, 
leading to assembly of a cleav-
age complex containing the 
foreign DNA, crRNA, and Cas9 
protein and resulting in cleavage 
of the invading DNA
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CRISPR and gene editing
In 2013, Dr. Feng Zhang at the Massachusetts Institute of 
Technology published the first report of CRISPR-based 
human gene editing [6]. His work was based on the ground-
breaking studies of Emmanuelle Charpentier and Jen-
nifer Doudna, who had previously identified the key ele-
ments required for CRISPR-mediated cleavage [7]. Zhang 
and his team recognized the potential of CRISPR systems to 
produce highly targeted modifications in human genes and 
designed a method to express guide RNAs (the equivalent 
of the crRNAs), tracrRNA, and the Cas9 cleavage protein 
in human cells [6].
One of the key issues resolved by Zhang and his team 
was how to repair the cleaved DNA at the target site. In the 
absence of intervention, repair of the cleaved DNA ends 
occurs via non-homologous end joining (NHEJ) (Fig. 2). 
This is an error-prone process, often resulting in insertion 
or deletion of a small number of nucleotides (indels), and 
leading to unpredictable changes in the gene sequence. As 
a result, the target gene may or may not be inactivated after 
repair. Zhang and his team postulated that by introducing 
a homology repair template into the cells along with the 
CRISPR system, the cleaved DNA ends could be repaired 
via homology-directed repair (HDR), in a template-specific 
manner. Using this strategy, Zhang and his team were able to 
induce cleavage and repair via HDR at the EMX1 homeobox 
gene in human cells [6].
The principle advantages of CRISPR  gene editing, 
relative to other gene-editing techniques, are its specific-
ity and accuracy of editing, even for very small sequences. 
This is a product of the strong complementarity between 
the guide sequences (crRNAs) and their targets, as well as 
the precision of Cas cleavage at the target site [8, 9]. In 
addition, CRISPR has the advantage of simplicity, in that 
it requires, at a minimum, only a crRNA guide sequence, 
the Cas9 nuclease protein (from Streptococcus pyogenes), 
and a tracrRNA, to be functional [9, 10]. Additional func-
tionality is available through the use of CRISPR-associated 
nucleases from different microorganisms, such as the Cas13 
protein (from Leptotrichia shahii), which is an RNA-spe-
cific nuclease [8]. Cas proteins have also been engineered to 
perform different enzymatic functions, such as DNA meth-
ylation and base editing. These modifications have greatly 
Fig. 2  Mechanisms of CRISPR/
Cas9 gene editing. a A con-
struct that expresses a crRNA 
segment and the Cas9 protein 
is introduced into the target cell. 
b The target DNA is bound by 
the crRNA and Cas9 complex. 
c A double-strand break is 
introduced at the target site by 
the Cas9 nuclease. d The free 
ends of the DNA are subse-
quently repaired by the cell’s 
DNA repair mechanisms, either 
through error-prone non-homol-
ogous end joining (NHEJ) or, 
with the addition of a homology 
template, through homology-
directed repair (HDR)
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expanded the nucleic-acid modifying potential of CRISPR-
based systems [11, 12]
The possibilities offered by CRISPR technology are vast 
and apply to many areas of biology, from food production 
to environmental science. Within medicine, CRISPR-based 
treatments for genetic diseases and cancers are under devel-
opment and some have already entered clinical trials [13].
One of the most intriguing applications for CRISPR tech-
nology is in the area of infectious diseases. Inexpensive and 
reliable CRISPR diagnostics for viruses and bacteria are 
under development and CRISPR-based therapeutics are in 
the pipeline to treat many challenging infections, including 
hepatitis B virus (HBV), human immunodeficiency virus-1 
(HIV-1), and methicillin-resistant Staphylococcus aureus 
(MRSA). Unlike traditional diagnostic and therapeutic 
tools, CRISPR systems can be easily modified to target novel 
pathogens or resistance pathways. As such, they represent 
a powerful potential tool against emerging viruses, where 
speed of development is paramount. The risks of CRISPR-
based therapeutics include both “off-target” and “on-target” 
effects, and these risks will need to be addressed as CRISPR 
technologies move from the laboratory to the bedside.
CRISPR‑based diagnostics
CRISPR-based systems provide improved speed and accu-
racy in the detection of viral and bacterial nucleic acids 
[14, 15]. Two analogous diagnostic systems, known as 
DETECTR [16, 17] and SHERLOCK [18, 19], have been 
designed to detect RNA and DNA sequences respectively. In 
the first step, viral or bacterial sequences are amplified from 
clinical samples using recombinase polymerase ampli-
fication (RPA). The resulting DNA is then mixed with a 
CRISPR/Cas system that identifies and cleaves the sequence 
of interest. The Cas endonuclease used in this reaction 
has been engineered to display indiscriminate cleavage 
activity only after it is activated by binding to its target. 
For RNA (DETECTR), this is Cas12a ([16, 17] while for 
DNA (SHERLOCK) this is Cas13a ([18, 19]. After cleaving 
their target sequences, Cas12a and Cas13a begin indiscrimi-
nately cleaving other DNAs or RNAs in the solution. Thus, 
when a quenched reporter sequence is introduced, Cas12a or 
Cas13a will cleave the reporter sequence, resulting in a fluo-
rescent signal. However, if the target sequence is not present 
in the solution, Cas12a and Cas13a will not be activated and 
the reporter sequence remains quenched.
SHERLOCK and DETECTR are so sensitive that they are 
capable of single copy viral detection. Moreover, the enzy-
matic reactions work at 37 ºC, and do not require expensive 
thermal cyclers. They are also rapid, taking only 1–2 hours 
from start to finish. For these reasons, there is tremendous 
interest in using SHERLOCK and DETECTR as field-
deployable diagnostic tools for viruses such as Ebola, Zika, 
and Dengue [15, 20]. Recently, detection of SARS-CoV-2 
using DETECTR was reported, with a turnaround time of 
only 45 min and a 95% positive and 100% negative predic-
tive agreement with PCR techniques [21].
CRISPR strategies can also be used to facilitate detection 
of low-frequency sequences within clinical samples, such as 
antimicrobial-resistance genes, by improving the sensitiv-
ity of Next-Generation Sequencing (NGS). The Depletion 
of Abundant Sequences to Hybridization (DASH) strategy 
employs a pre-processing step in which high frequency 
targets that reduce the sensitivity of NGS, such as human 
mitochondrial ribosomal RNA genes, are cleaved with 
CRISPR/Cas9 [22]. After removal of these high-frequency 
targets, the pathogenic sequences of interest can then be eas-
ily amplified. This strategy was used to amplify fungal and 
parasitic sequences from cerebrospinal fluid samples with 
greatly increased sensitivity [22]. An alternative CRISPR-
based strategy, called FLASH (Finding Low Abundance 
Sequences by Hybridization), uses alkaline phosphatase to 
block all sequences in the sample. A CRISPR/Cas system is 
then used to partially digest the sequence of interest, which is 
ligated to universal sequencing adapters and amplified, with 
very little amplification of other sequences in the sample 
[23]. FLASH-NGS was used to identify antibiotic-resistance 
genes in tracheal aspirates from patients with Staphylococ-
cus aureus pneumonia [23]. The approach achieved 5000-
fold enrichment of the target genes, relative to NGS alone. 
It was also used successfully to identify malaria-resistance 
genes from dried blood spot samples [23]. Once again, the 
sensitivity of detection with FLASH-NGS was much greater 
than with NGS alone.
These extraordinary techniques are likely to find quick 
application in clinical laboratories. Not only are they highly 
sensitive, they are also fast and inexpensive, an irresistible 
combination [21–24]. Moreover, unlike CRISPR therapeu-
tics, there are no significant risks to patients that need to be 
addressed.
CRISPR‑based therapies in the treatment of acute 
and chronic viral infections
Viruses are encapsulated pieces of viral DNA or RNA that 
invade living cells and hijack their intracellular processes 
to enable their own replication. Given their intracellular 
localization and their dependence on cellular proteins for 
their replication and survival, they are obvious targets for 
CRISPR-based gene editing therapies.
Viral infections exist in three distinct states: lytic infec-
tion, latent infection and chronic infection. In lytic infection, 
the virus is actively replicating and producing viral progeny, 
or virions. After the viral genomes are packaged into protein 
coats, or capsids, they are released through cell lysis, thereby 
destroying the host cell [25]. Some viruses can also cause 
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latent infection, in which the virus enters a dormant state in 
which it can remain for years. Many important human patho-
gens, including Herpes Simplex 1 (HSV-1), Epstein–Barr 
virus (EBV), Cytomegalovirus (CMV), human herpesvirus 
6 (HHV-6), Hepatitis B virus (HBV), polyomavirus, and 
parvovirus, cause latent infections [25, 26]. Finally, chronic 
infection represents a state of continuous low-level viral rep-
lication, leading to chronic organ damage. Chronic infection 
is typical of several important human pathogens, including 
HBV and HIV-1 [27]. These two infections cause enormous 
morbidity and mortality, with 250 million people world-
wide currently suffering from chronic HBV infection [28], 
and almost 40 million from chronic HIV-1 infection [29].
In latent and chronic viral infection, the viral genome is 
maintained indefinitely inside the host cell, either integrated 
into the host genome or as free-floating viral minichromo-
somes. Once the virus has taken up residence inside the host 
cell, it is very challenging to treat. However, CRISPR-based 
systems can be used to target viral genomes inside the host 
cell, rendering them incapable for transcription and repli-
cation (see below). Thus, CRISPR gene editing offers the 
potential of a cure for these challenging chronic infections.
Although the concept makes intuitive sense, there are 
logistical challenges that need to be overcome. First, the 
CRISPR system has to be delivered to the target cells. Sec-
ond, the system must accurately target viral genomes that 
are in a constant state of evolution; this is particularly chal-
lenging with HIV-1, due to its high rate of mutation and 
considerable genetic diversity even within a single host [30]. 
Third, there must be a strategy to prevent reinfection of the 
newly “cured” cells from other viral reservoirs within the 
body. Finally, the system must not induce unintended effects 
at “off-target” sites in the host genome.
In spite of these challenges, considerable progress has 
been made in developing CRISPR-based therapies for 
chronic viral infections. In one study, a CRISPR/Cas9 sys-
tem was used to knock down HBV in a human hepatocyte 
cell line and in a mouse model of HBV [31]. Encouragingly, 
even after 4 weeks of continuous CRISPR/Cas9 expres-
sion in the mouse model, no off-target cleavage events were 
detected. Another study employed a modified “base editing” 
Cas9 protein to target HBV [32]. Instead of cleaving the 
DNA at the target site, the Cas9 base editing protein induced 
a nucleotide modification, resulting in a nonsense codon that 
prevented viral protein translation. By avoiding the creation 
of double-strand breaks, this base editing strategy reduces 
the risk of chromosomal rearrangements at the target site 
(with their potential to cause cancer), as well as limiting the 
danger associated with off-target effects.
HIV-1 is a complex and elusive virus and its ability to 
mutate allows it to develop resistance to most therapies over 
time [33]. However, several investigators have designed 
CRISPR systems that can target HIV-1 genes integrated 
into host DNA, thereby eliminating the virus in situ [33, 
34]. In one study, investigators targeted the HIV-1 genome 
in a human T-cell line using a CRISPR system and either a 
single guide RNA or two guide RNAs simultaneously [33]. 
The use of a single-guide RNA lead to rapid viral resist-
ance, but dual targeting with two guide RNAs caused com-
plete suppression of viral replication, without evidence of 
viral escape [33]. Moreover, persistent co-expression of 
the CRISPR/Cas9 system in HIV-1-eradicated cells pre-
vented reinfection [35, 36]. Recently, a CRISPR/Cas9 sys-
tem was used to eradicate HIV-1 from a humanized mouse 
model of the disease [37]. No off-target effects were iden-
tified after sequencing more than 100 predicted off-target 
sites. Finally, in an ex vivo therapeutic approach, CRISPR/
Cas9 technology was used to modify the CCR5 receptor in 
CD4 + germline cells, making them resistant to de novo HIV 
infection [38]. This raises the possibility of ex vivo treatment 
for HIV-1 patients, in which the patient’s own T cells are 
extracted, modified outside the body using CRISPR, and 
then reintroduced to provide the patient with a functioning 
HIV-1-resistant immune system [39, 40].
CRISPR/Cas9 systems have also been used to eradicate 
porcine endogenous retroviruses (PERVs) in pigs. PERVs 
are viruses that are integrated into the porcine genome 
and are a major barrier to xenotransplantation (i.e., trans-
plant of pig organs into human recipients). In an effort to 
make pig organs PERV-free, CRISPR/Cas9 systems were 
used to eliminate PERVs from porcine cell lines by target-
ing the highly conserved PERV polymerase gene. This led 
to a 1000-fold reduction in PERV viral burden [16]. Subse-
quently, somatic cell nuclear transfer was used to generate 
PERV-free pigs that could potentially be used to grow organs 
for xenotransplantation [18].
A number of other human DNA viruses have been tar-
geted using CRISPR/Cas9 systems. These include herpes 
simplex virus-1 (HSV-1) [41, 42], Epstein Barr Virus (EBV) 
[14, 43, 44], human cytomegalovirus (CMV) [41], human 
papilloma virus (HPV) [45–47], and JC polyomavirus [48]. 
However, many important human pathogens, including 
the flaviviruses (Zika virus, West Nile virus, Yellow fever, 
and dengue), rotaviruses, and coronaviruses (SARS-CoV, 
MERS-CoV, SARS-CoV-2) have RNA genomes. Recently, 
two CRISPR systems were  developed that target RNA 
sequences. One such system uses the Cas9 protein, which 
has some intrinsic affinity for RNA, and a separate DNA oli-
gomer containing the PAM sequence. The PAM oligomer 
binds to the target RNA sequence at the intrinsic PAM 
sequence thereby forming the double-stranded target neces-
sary for Cas9 cleavage [4, 49]. A second RNA-modifying 
CRISPR system uses a family of RNA-targeted nucleases 
called Cas13 proteins [5, 8, 50]. This strategy has been pro-
posed as a therapeutic approach for SARS-CoV-2, the virus 
causing Coronavirus 2019 (COVID-19) disease [51]. The 
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concept entails introduction of a CRISPR/Cas13 system 
into airway epithelial cells, along with guide RNAs targeted 
against the replicase-transcriptase and spike protein genes 
of the SARS-CoV-2 virus, all under the control of a tissue-
specific promoter. Delivery would be via aerosolization of 
a modified adeno-associated virus, a non-pathogenic human 
virus with affinity for the airway epithelium [51]. Recently, 
this strategy was tested in airway epithelial cell where it was 
successful in cleaving synthesized SARS-CoV-2 RNA frag-
ments [52]. The authors noted that the strategy could be used 
to target 90% of known coronaviruses using only 6 guide 
RNAs targeted to conserved sequences. Further studies will 
be required to determine whether the strategy is effective 
against live SARS-CoV-2 virus and whether it is safe for 
use in patients. 
Although CRISPR therapies for COVID-19 are unlikely 
to enter clinical practice during the current pandemic, they 
hold promise as a therapeutic approach that could be rapidly 
deployed for future viral epidemics.
CRISPR “VACCINES”
Traditional vaccination involves introducing viral or bac-
terial antigens into the host, resulting in  the generation 
of a  targeted antibody response and/or a targeted T cell 
response [53, 54]. The response is host-specific, however, 
with significant variability in the quantity and quality of the 
antibodies produced between individuals [53]. Moreover, 
some viruses, such as HIV-1, only generate neutralizing anti-
bodies in a small minority of individuals, making vaccine 
design challenging.
An alternative strategy is to engineer patient B cells to 
produce neutralizing antibodies. Using CRISPR systems, 
human B cells have been modified to produce HIV-1-spe-
cific broadly neutralizing antibodies (bNAb), that can sup-
press HIV-1 viremia [55]. In a recent study, CRISPR-based 
cleavage and homology-directed repair were used to edit the 
heavy chain locus in activated B cells from human patients 
to produce bNAbs. These B cells were then transferred into 
mice, where they produced sufficient levels of antibody 
to confer immunity [55]. This strategy would potentially 
eliminate the inter-individual variability associated with 
traditional vaccination and might also be used to generate 
immunity against viruses, such as HIV-1, for which tradi-
tional vaccines have thus far proven ineffective.
CRISPR‑based therapies for bacterial infections
Although CRISPR systems evolved in bacteria, they can 
also be used to create anti-bacterial therapeutics that can 
be delivered through the cell wall using bacteriophages, 
which are viruses that infect bacteria. Naturally occurring 
bacteriophages have previously been used to treat local-
ized skin infections [56] as well as an intra-abdominal 
Acinetobacter baumanii infection [57] and a drug-resistant 
Staphylococcus aureus osteomyelitis [58]. In these cases, 
the bacteriophages were selected from phage libraries rather 
than engineered [59], however the use of bacteriophages to 
deliver engineered therapeutics is an area of growing 
interest [60].
Bacteriophages that can deliver CRISPR systems to 
pathogenic bacteria have been reported for both Staphylo-
coccus aureus [61, 62] and Escherichia coli [63]. Cleav-
age targets for the CRISPR systems included: (1) bacterial 
virulence factors (resulting in decreased virulence) [25, 26, 
61]; (2) antibiotic-resistance genes (resulting in improved 
susceptibility to antibiotics) [63]; and (3) genes unique to 
the bacterial species (resulting in highly specific bacterial 
killing) [62]. Unlike antibiotics, engineered bacteriophages 
should hypothetically have an extremely narrow spectrum 
of action, killing the bacteria of interest while sparing non-
pathogenic commensal bacteria. Off-target effects on host 
cells should also be non-existent, as the CRISPR constructs 
are transcribed only inside the bacteria.
In vivo data indicate that CRISPR bacteriophages are 
highly effective against their target bacteria [61, 62, 64]. 
Results in vivo, however, have been more mixed. Treatment 
of skin and soft tissue infections in animal models was suc-
cessful [63, 64], but treatment of Staphylococcus aureus 
osteomyelitis in a rat model was not [64]. This may be a 
result of poor bacteriophage penetration into the bone. Fur-
ther in vivo research is required to optimize bacteriophage 
delivery and dosing, as well as to ensure safety and minimize 
side effects.
Impediments to CRISPR therapeutics
The principle risks of CRISPR-based therapeutics are “off-
target” effects, namely DNA or RNA modifications at unan-
ticipated sites, and “on-target” effects, namely unintended 
DNA or RNA modifications at the target site.
Off-target effects occur when partial homologies between 
the guide RNA(s) and off-target genomic sequences result 
in unintended modifications distant from the target site 
[65, 66]. These effects are not entirely predictable, as they 
depend not only on the degree and location of sequence 
homology but also on gRNA structure. To complicate mat-
ters further, the only way to identify all off-target effects is to 
perform whole-genome sequencing [67]. A number of strate-
gies have been employed to reduce off-target effects. These 
include careful selection of gRNA sequences to minimize 
homologies as well as the use of truncated or 5′ guanine 
capped gRNAs that confer higher specificity [68, 69]. Engi-
neered Cas nucleases with increased cleavage specificity can 
be also used to limit off-target effects [70, 71]. Finally, the 
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use of paired Cas nucleases that only nick one DNA strand, 
thereby requiring the binding of two gRNA sequences to 
opposite DNA strands in close proximity, has also been 
shown to greatly improve specificity [72].
On-target effects comprise all unintended sequence modi-
fications at the target site. These include base pair inser-
tions and deletions, as well as inversions and recombination 
events [73, 74]. On-target effects are a significant concern 
in genetic engineering, where they reduce efficiency and 
potentially damage the target gene, but are less concerning 
when the target is a pathogenic sequence. However, they 
cannot be ignored given the risk of recombination events 
such as between an integrated viral sequence and the host 
genome. Strategies to reduce on-target effects include using 
a modified Cas9 nuclease that increases the frequency of 
homology repair and an optimized homology repair tem-
plate, as well as inhibiting non-homologous end-joining 
through the use of NHEJ pathway inhibitors [75].
CRISPR Therapeutics in Human Trials
CRISPR systems are already being trialled in phase 1 stud-
ies in human patients. Most of these trials involve ex vivo 
CRISPR therapy, meaning that the patient’s cells (or donor 
cells) are harvested, modified in the laboratory, and then 
reintroduced into the patient. In 2019, a group from China 
reported the successful bone marrow transplantation of 
an HIV-1-positive patient with acute lymphocytic leuke-
mia for whom the hematopoietic progenitor cells had been 
CCR5-ablated using CRISPR in order to prevent HIV infec-
tion [76]. CCR5 ablation was confirmed in a percentage of 
the patient’s T cells after engraftment and whole genome 
sequencing showed no evidence of off-target effects. Another 
small phase 1 trial included 3 patients with refractory cancer 
(two with advanced myeloma and one with liposarcoma) 
whose T cells were harvested, modified using CRISPR 
engineering to express a T cell receptor specific to the NY-
ESO-1 tumor antigen, and then reintroduced into the patients 
[13]. Expression of the engineered T-cells was confirmed in 
all 3 patients for at least 100 days. At the end of the 9 month 
follow-up period, two patients were alive and one patient had 
died. Of note, chromosomal translocations were identified 
in all of the engineered T cell populations; however, these 
did not appear to confer a growth advantage to the modified 
T cells.
The first trial of in vivo CRISPR gene therapy in human 
patients began in early 2020. In the study, pediatric patients 
with a congenital  retinal disease  called Leber congeni-
tal aumaurosis will receive a CRISPR-based therapeu-
tic system that will correct the single base pair mutation 
causing the disease and will be delivered to the retina via 
local  injection of an engineered adenovirus vector [77]. 
Results of the trial are still pending. 
Progress in the field of CRISPR therapeutics has been 
extremely fast, from the first CRISPR gene-editing system 
in human cells in 2013 to the first phase 1 clinical trial in 
2020. Given the widespread interest in CRISPR-based thera-
pies for many diseases, ranging from monogenic diseases 
such as sickle cell disease and hemophilia to complex dis-
eases such as cancer, progress is likely to continue at break-
neck speed. As safety issues are addressed, the feasibility of 
using CRISPR therapeutics in human patients with infec-
tious diseases will only increase.
Conclusion
The discovery of CRISPR repeats in bacteria was initially 
considered of minor importance outside the field of micro-
biology. However, CRISPR technology has emerged as a 
landmark discovery in the field of genetic engineering and is 
poised to have a major impact in many areas of clinical med-
icine. In this review, we have outlined potential applications 
for CRISPR technology in infectious diseases, including the 
development of rapid, low-cost diagnostics, the treatment 
of acute and chronic viral infections, and the treatment of 
resistant bacterial infections. CRISPR-based diagnostics and 
therapeutics will likely appear in clinical practice in the near 
future, and clinicians should be aware of their extraordinary 
potential, as well as their potential risks.
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